The University of Kent, Canterbury, Kent, CT2 7NZ, T +44 (0)1227 764000
Biosciences contract research start-up acquired by major European company
Successful biotech start-up Cangenix – which is based at the Universitys School of Biosciences – has been acquired by Argenta, part of Galapagos NVs service division, one of Europes largest contract research organisations.
Cangenix was launched 15 months ago when Professor David Brown, formerly of Pfizer, was appointed chair of Structural Biology at the University. It offers crystallography – a structure-based drug design tool – and biophysics services to the pharmaceutical and biotech industry. Bioscience research students also benefit from the companys cutting edge expertise.
Professor Brown said: Im hoping there will be opportunities to forge even stronger links between the University and Argenta in the Drug Discovery area.
'Cangenix will continue to operate at the School of Biosciences premises, offering structure based drug design contract research through Argenta. But Im hoping also that we will be able to widen links beyond Biosciences to other areas of synergy within the University.'
Story published at 12:15pm 4 February 2013